Greenwich LifeSciences, Inc. (GLSI) is a publicly traded Healthcare sector company. As of May 21, 2026, GLSI trades at $26.82 with a market cap of $372.41M and a P/E ratio of -22.14. GLSI moved +3.57% today. Year to date, GLSI is +28.81%; over the trailing twelve months it is +165.24%. Its 52-week range spans $7.78 to $34.10. Analyst consensus is buy with an average price target of $47.50. Rallies surfaces GLSI's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Greenwich LifeSciences delays FY2025 10-K, FLAMINGO-01 arm shows 70-80% recurrence drop: Greenwich LifeSciences expects its audited FY2025 Form 10-K and Q1 10-Q by end-May after auditors address accounts payable from accelerated global Phase III trial spending and higher European patient screening. Unaudited cash totaled $10.5 million at March 31, while FLAMINGO-01’s non-HLA-A*02 arm (250 patients) shows a preliminary 70-80% recurrence reduction.
| Metric | Value |
|---|---|
| Price | $26.82 |
| Market Cap | $372.41M |
| P/E Ratio | -22.14 |
| EPS | $-1.21 |
| Dividend Yield | 0.00% |
| 52-Week High | $34.10 |
| 52-Week Low | $7.78 |
| Volume | 816 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-15.79M |
| Gross Margin | 0.00% |
2 analysts cover GLSI: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $47.50.